Binding of the imidazoline ligand 3H-2-benzofuranyl-2-imidazoline (BFI) to human brain and platelets. Potentiation by tranylcypromine and role of MAO isoforms.
Steinberg
M I
MI
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA. MIS@Lilly.com
Wiest
S A
SA
Pickard
R T
RT
Chen
K
K
Shih
J C
JC
D000818:Animals; D001572:Benzofurans / Q000493:pharmacokinetics*; D001792:Blood Platelets / Q000378:metabolism*; D001921:Brain / Q000378:metabolism*; D002462:Cell Membrane / Q000378:metabolism; D002540:Cerebral Cortex / Q000378:metabolism; D006801:Humans; D019329:Idazoxan / Q000494:pharmacology; D007093:Imidazoles / Q000493:pharmacokinetics*; D054755:Imidazoline Receptors; D007527:Isoenzymes / Q000378:metabolism; D007700:Kinetics; D008024:Ligands; D008995:Monoamine Oxidase / Q000378:metabolism*; D051381:Rats; D011955:Receptors, Drug / Q000378:metabolism*; D014191:Tranylcypromine / Q000494:pharmacology*; D014316:Tritium
D001572:Benzofurans; D007093:Imidazoles; D054755:Imidazoline Receptors; D007527:Isoenzymes; D008024:Ligands; D011955:Receptors, Drug; D014316:Tritium; D014191:Tranylcypromine; C103723:2-(2-benzofuranyl)-2-imidazoline; D008995:Monoamine Oxidase; D019329:Idazoxan